FDA Approves Option for Allergic Reactions in Infants and Young Children

The FDA has approved AUVI-Q (epinephrine injection, USP) 0.1 mg auto-injector for the treatment of allergic reactions, including anaphylaxis, in infants and young children.

This is the first and only epinephrine auto-injector approved with a needle length and dose specifically designed for infants and children weighing 16.5 to 33 pounds.

Common adverse effects include fast, irregular heartbeat, sweating, shakiness, headache, paleness, feelings of over excitement, nervousness, or anxiety, weakness, dizziness, nausea and vomiting, or breathing problems. Rarely, injection site infections may occur with use of AUVI-Q.

—Michael Potts

Reference:

U.S. FDA Approves Kaléo’s AUVI-Q® (Epinephrine Injection, USP) 0.1 mg auto-injector for life-threatening allergic reactions in infants and small children [press release]. https://kaleopharma.com/u-s-fda-approves-kaleos-auvi-q-epinephrine-injection-usp-0-1-mg-auto-injector-for-life-threatening-allergic-reactions-in-infants-and-small-children/.